Researchers at Ngwa have suggested FBL-03G, a non-psychoactive derivative of a cannabis flavonoid, could have "significant therapy potential" for pancreatic cancer, which has a five-year survival rate of 9%. The team found FBL-03G not only killed local cancer cells, but also inhibited metastatic growth elsewhere in the body. The researchers will conclude pre-clinical studies by next year.
Researchers at Harvard University have suggested FBL-03G, a non-psychoactive derivative of a cannabis flavonoid, could have "significant therapy potential" for pancreatic cancer, which has a five-year survival rate of 9%. The team found FBL-03G not only killed local cancer cells, but also inhibited metastatic growth elsewhere in the body. The researchers will conclude pre-clinical studies by next year.